CytomX Therapeutics Inc. (6C1)
XBER 
Summary
6C1 Chart
CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling
CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. CTMX also now notes it plans to start combination work with CX-2051 and bevacizumab in Q1'26. Financially, CTMX holds ~$158M pro forma cash, guiding for runway through Q2'27, with further fundraising, such as using the Open Market Sales Agreement, possible.
CytomX Therapeutics: Leaning Into The Hype, But What's Next?
CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory colorectal cancer, with disease control in nearly all patients and confirmed responses. CTMX holds a strong financial position with $34.2 million in cash and $109.4 million in investments, supporting operations through Q2 2027.
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.07 per share a year ago.
CytomX Therapeutics Inc. (6C1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has CytomX Therapeutics Inc. ever had a stock split?
CytomX Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sean A. McCarthy DPHIL CEO | XBER Exchange | US23284F1057 ISIN |
| US Country | 119 Employees | - Last Dividend | - Last Split | 8 Oct 2015 IPO Date |
Overview
CytomX Therapeutics, Inc. is a biopharmaceutical company with a strong focus on the field of oncology. It specializes in creating innovative conditionally activated biologics that are designed to act specifically within the tumor microenvironment. By leveraging its unique conditional activation platform technology, CytomX aims to revolutionize oncology biologics research and development. This includes advancing the validation of targets for antibody-drug conjugates (ADCs), enhancing the therapeutic efficacy of novel T-cell engagers (TCEs) against solid tumors, and improving the therapeutic index of immune modulators such as cytokines. Furthermore, the company conducts preclinical research in areas outside oncology, utilizing its PROBODY platform. Established in 2008, CytomX Therapeutics, Inc. is headquartered in South San Francisco, California, demonstrating its commitment to innovation and development in the fight against cancer.
Products and Services
- CX-904
This product is a T-cell-engaging bispecific antibody, focusing on targeting the epidermal growth factor receptor (EGFR) present on the surface of tumor cells, as well as the CD3 receptor on T-cells. The aim is to enhance the body's immune response against cancerous cells, offering a novel approach to cancer therapy.
- CX-2051
A conditionally activated antibody-drug conjugate (ADC) optimized for treating EpCAM-expressing epithelial cancers, including colorectal cancer. CX-2051 is designed to improve the therapeutic index by selectively targeting cancer cells, thereby reducing the impact on healthy cells and minimizing side effects.
- CX-801
Interferon alpha-2b PROBODY cytokine that represents a refined approach to leveraging cytokine therapy for cancer treatment. By conditionally activating interferon alpha-2b, CX-801 aims to concentrate its therapeutic effects within the tumor microenvironment, potentially reducing systemic side effects and improving patient outcomes.
- CX-2029
This conditional activated ADC targets CD71, a transferrin receptor that is often overexpressed in cancer cells. CX-2029 is designed to deliver cytotoxic agents directly to the tumor cells, thus potentially offering a more targeted and efficient therapy with fewer off-target effects.
- BMS-986288
A PROBODY version of ipilimumab, this product is non-fucosylated to enhance its effectiveness. By retaining the mechanism of action of the original ipilimumab, a monoclonal antibody approved for the treatment of various cancers, BMS-986288 aims to improve safety and efficacy profiles through targeted activation within the tumor environment.
In addition to developing its proprietary pipeline, CytomX Therapeutics has forged strategic collaborations with industry giants such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. These partnerships aim to expand the reach and impact of its novel therapeutics, advancing the pursuit of more effective cancer treatments.
